LivaNova PLC (LIVN)
| Market Cap | 3.61B |
| Revenue (ttm) | 1.03B |
| Net Income (ttm) | -103.13M |
| Shares Out | 53.44M |
| EPS (ttm) | -1.97 |
| PE Ratio | n/a |
| Forward PE | 24.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 211,422 |
| Open | 66.61 |
| Previous Close | 66.02 |
| Day's Range | 65.97 - 67.66 |
| 52-Week Range | 58.18 - 93.89 |
| Beta | 0.90 |
| Analysts | Buy |
| Price Target | 102.34 (+51.5%) |
| Earnings Date | May 4, 2022 |
About LIVN
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device tha...
Financial Performance
In 2021, LivaNova's revenue was $1.04 billion, an increase of 10.82% compared to the previous year's $934.24 million. Losses were -$135.82 million, -61.06% less than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for LIVN stock is "Buy." The 12-month stock price forecast is 102.34, which is an increase of 51.55% from the latest price.
News
LivaNova to Present at the Goldman Sachs Global Healthcare Conference
LONDON--(BUSINESS WIRE)--LivaNova PLC announced CEO Damien McDonald will present in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15.
LivaNova (LIVN) Lags Q1 Earnings Estimates
LivaNova (LIVN) delivered earnings and revenue surprises of -7.69% and 3.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
LivaNova Reports First-Quarter 2022 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC, a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2022.
LivaNova Initiates Targeted Commercial Launch of the Essenz Patient Monitor for Cardiopulmonary Bypass Procedures
LONDON--(BUSINESS WIRE)--LivaNova PLC today announced receipt of regulatory approvals and the start of a targeted commercial launch for the Essenz Patient Monitor.
LivaNova to Announce First-Quarter 2022 Results
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC will host a conference call to discuss its first-quarter 2022 results on Wednesday, May 4, 2022 at 1 p.m. London time (8 a.m. EDT).
LivaNova Announces 250th Unipolar Depression Patient Implanted in RECOVER Clinical Study
LONDON--(BUSINESS WIRE)-- #depression--LivaNova PLC today announced the 250th unipolar depression patient has been implanted in the RECOVER clinical study.
LivaNova Announces First Patient Implanted in OSPREY Clinical Study for Patients Coping with Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)-- #livn--LivaNova PLC announced the first patient implanted in clinical study, “Treating Obstructive Sleep Apnea using Targeted Hypoglossal Neurostimulation.”
LivaNova (LIVN) Surpasses Q4 Earnings and Revenue Estimates
LivaNova (LIVN) delivered earnings and revenue surprises of 14% and 2.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
LivaNova Reports Fourth-Quarter and Full-Year 2021 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today reported results for the quarter and full year ended December 31, 2021.
Can LivaNova (LIVN) Keep the Earnings Surprise Streak Alive?
LivaNova (LIVN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
LivaNova to Announce Fourth-Quarter and Full-Year 2021 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC will host a conference call to discuss its fourth-quarter and full-year 2021 results on Wed., Feb. 23, 2022 at 1 p.m. London (8 a.m. ET)
LivaNova to Present Scientific Data on VNS Therapy for Drug-Resistant Epilepsy at American Epilepsy Society 2021 Annu...
LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC today announced its participation in the American Epilepsy Society Annual Meeting taking place December 3 – 7 in Chicago, Illinois.
LivaNova to Present Scientific Data on VNS Therapy for Difficult-to-Treat Depression at 4th International Brain Stimu...
LONDON--(BUSINESS WIRE)--LivaNova PLC today announced its participation in the 4th International Brain Stimulation Conference, taking place December 6 - 9 in Charleston, S.C.
LivaNova to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
LONDON--(BUSINESS WIRE)-- #cardiovascular--LivaNova PLC announced Damien McDonald, CEO, will participate in discussions at the Piper Sandler 33rd Annual Virtual Healthcare Conference on Dec. 1.
LivaNova Comments on Decision by Court of Appeal of Milan
LONDON--(BUSINESS WIRE)--LivaNova commented on the decision delivered today by the Court of Appeal of Milan for LivaNova to pay damages as a result of a civil action.
LivaNova to Present at the 2021 Stifel and Jefferies Healthcare Conferences
LONDON--(BUSINESS WIRE)-- #cardiovascular--LivaNova announced CEO Damien McDonald will present at Stifel 2021 Virtual Healthcare Conference and at Jefferies 2021 London Healthcare Conference.
LivaNova Announces 2021 Virtual Investor Day
LONDON--(BUSINESS WIRE)-- #cardiovascular--LivaNova today announced it will host a virtual Investor Day on December 7 from 8 a.m.-12 p.m. Central Time (9 a.m.-1 p.m. Eastern Time).
LivaNova Shares Move Higher On Street-Beating Q3 Earnings
LivaNova PLC (NASDAQ: LIVN) posted Q3 sales of $253.2 million, +5.5% Y/Y on a reported basis and 5% on a constant-currency basis, beating the consensus of $245.27 million. Excluding Heart Valves busines...
LivaNova (LIVN) Q3 Earnings and Revenues Surpass Estimates
LivaNova (LIVN) delivered earnings and revenue surprises of 51.11% and 3.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
LivaNova Reports Third Quarter 2021 Results
LONDON--(BUSINESS WIRE)-- #cardiovascular--LivaNova PLC, a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2021.
LivaNova (LIVN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LivaNova (LIVN) Sees Hammer Chart Pattern: Time to Buy?
LivaNova (LIVN) has been struggling lately, but the selling pressure may be coming to an end soon.
LivaNova to Host Conference Call for Third Quarter 2021 Results
LONDON--(BUSINESS WIRE)-- #cardiovascular--LivaNova PLC will host a conference call to discuss its third quarter 2021 results on Wednesday, Nov. 3, 2021 at 12 p.m. London/8 a.m. Eastern time.
